Hospital
Desert Valley Hospital, LLC
Desert Valley Hospital, LLC was paid $92.81M by Medicaid between Jan 2018 and Dec 2024, across 288 billing codes. Its largest line is 0121, — 68% of everything it billed.
33Billing provider infoDESERT VALLEY HOSPITAL, LLC
VICTORVILLE, CA 92395
VICTORVILLE, CA 92395
33aNPI1851396576assigned 06/17/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$92.81M
24GClaims1,057,906
24DCodes billed288
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#26 of 410
Median peer was paid$6.90M
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 172,509 | $27.10M | |
| 2019 | 189,025 | $24.80M | |
| 2020 | 147,978 | $21.34M | |
| 2021 | 126,898 | $8.17M | |
| 2022 | 130,568 | $3.50M | |
| 2023 | 156,725 | $4.09M | |
| 2024incomplete | 134,203 | $3.81M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0121 | 68% | 8,628 | 7,138 | $62.67M | |
| 0450 | Emergency room services | 3.5% | 78,390 | 70,089 | $3.21M |
| 0112 | 2.6% | 788 | 626 | $2.41M | |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.3% | 44,678 | 41,060 | $2.10M |
| 0200 | 2.1% | 527 | 455 | $1.98M | |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 12,783 | 12,289 | $1.85M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 11,725 | 11,261 | $1.12M |
| 0122 | 1.2% | 405 | 308 | $1.08M | |
| 0171 | Inj, epinephrine (belcher) | 1.2% | 1,145 | 885 | $1.08M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 28,314 | 23,919 | $709K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,361 | 12,673 | $704K |
| 80053 | Comprehensive metabolic panel | <1% | 51,041 | 47,599 | $686K |
276 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 25,758 | $660K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,359 | $606K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 57,243 | $542K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,516 | $496K |
| Z7502 | <1% | 12,852 | $468K | |
| 0206 | <1% | 354 | $460K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,315 | $438K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,017 | $391K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,090 | $361K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,069 | $360K |
| 0762 | <1% | 6,984 | $341K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,784 | $315K |
| 84484 | <1% | 24,123 | $312K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,533 | $266K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 7,666 | $248K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,202 | $242K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,863 | $239K |
| 99499 | <1% | 4,531 | $238K | |
| 99070 | <1% | 33,821 | $232K | |
| 70486 | <1% | 1,458 | $219K | |
| 59025 | Fetal non-stress test | <1% | 11,254 | $214K |
| G0378 | Hospital observation service, per hour | <1% | 3,593 | $211K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,713 | $207K |
| 99284 | Emergency room visit (serious) | <1% | 2,619 | $190K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 4,169 | $188K |
| 71045 | Radiologic examination, chest; single view | <1% | 17,664 | $184K |
| 99285 | Emergency room visit (most serious) | <1% | 1,278 | $180K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,274 | $169K |
| 81001 | <1% | 37,440 | $160K | |
| 71250 | <1% | 823 | $157K | |
| 84702 | <1% | 8,851 | $136K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,979 | $134K |
| 83880 | <1% | 6,824 | $126K | |
| 93971 | <1% | 1,011 | $117K | |
| 76801 | <1% | 2,209 | $115K | |
| 99221 | <1% | 969 | $111K | |
| J3490 | Unclassified drugs | <1% | 15,869 | $105K |
| Z7610 | <1% | 7,265 | $102K | |
| 0360 | <1% | 2,383 | $98K | |
| 83690 | <1% | 10,739 | $94K | |
| 83735 | <1% | 11,846 | $89K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,534 | $88K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,681 | $87K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,425 | $84K |
| 72131 | <1% | 508 | $76K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 907 | $72K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,185 | $68K |
| 85730 | <1% | 9,706 | $67K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,362 | $66K |
| 81025 | <1% | 8,852 | $60K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,228 | $58K |
| 90715 | <1% | 1,749 | $58K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,101 | $58K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,589 | $57K |
| 83605 | <1% | 4,403 | $57K | |
| 73030 | <1% | 2,301 | $52K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,087 | $51K |
| 73130 | <1% | 2,221 | $51K | |
| 0250 | <1% | 12,433 | $49K | |
| 87040 | <1% | 3,924 | $48K | |
| 72100 | <1% | 1,816 | $47K | |
| 93458 | <1% | 66 | $47K | |
| 85610 | <1% | 10,639 | $46K | |
| 81002 | <1% | 11,664 | $44K | |
| 73610 | <1% | 1,892 | $44K | |
| 73562 | <1% | 2,237 | $44K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 1,114 | $42K |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,194 | $42K |
| 73630 | <1% | 1,807 | $38K | |
| 85379 | <1% | 2,945 | $36K | |
| 82962 | <1% | 7,359 | $36K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 227 | $35K |
| 73110 | <1% | 1,389 | $33K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,300 | $31K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 9,913 | $31K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,708 | $31K |
| 0710 | <1% | 5,486 | $30K | |
| 94760 | <1% | 3,695 | $27K | |
| 93017 | <1% | 572 | $27K | |
| 72040 | <1% | 1,119 | $26K | |
| 80061 | Lipid panel | <1% | 1,879 | $25K |
| 82150 | <1% | 2,857 | $23K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,118 | $22K |
| Z9725 | <1% | 506 | $21K | |
| 74018 | <1% | 1,198 | $20K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 102 | $19K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,085 | $19K |
| 86850 | <1% | 2,040 | $19K | |
| 99199 | Unlisted special service, procedure or report | <1% | 451 | $19K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 794 | $18K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,137 | $18K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 573 | $16K |
| 93970 | <1% | 81 | $15K | |
| 99218 | <1% | 128 | $15K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,200 | $14K |
| 85027 | <1% | 1,774 | $13K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 660 | $13K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 661 | $13K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,622 | $12K |
| 12002 | <1% | 716 | $12K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,123 | $12K |
| 12001 | <1% | 676 | $11K | |
| 86901 | <1% | 2,202 | $11K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 907 | $11K |
| 73080 | <1% | 435 | $11K | |
| 87807 | <1% | 1,607 | $11K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,276 | $11K |
| 73090 | <1% | 569 | $11K | |
| 0270 | <1% | 4,329 | $11K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 853 | $10K |
| 73700 | <1% | 55 | $9K | |
| Z7500 | <1% | 256 | $9K | |
| 87070 | <1% | 745 | $8K | |
| 76830 | Ultrasound, transvaginal | <1% | 136 | $8K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 152 | $8K |
| 84439 | <1% | 620 | $8K | |
| 12011 | <1% | 392 | $8K | |
| 82805 | <1% | 206 | $8K | |
| 94060 | <1% | 130 | $8K | |
| 86900 | <1% | 2,140 | $7K | |
| 29125 | <1% | 1,031 | $7K | |
| 0481 | <1% | 621 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,991 | $7K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,766 | $7K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,063 | $7K |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 551 | $6K |
| 85007 | <1% | 1,761 | $6K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,594 | $6K |
| 86141 | <1% | 755 | $6K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,732 | $6K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 365 | $5K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,540 | $5K |
| 86703 | <1% | 371 | $5K | |
| 73502 | <1% | 211 | $5K | |
| 71101 | <1% | 124 | $5K | |
| 87340 | <1% | 285 | $4K | |
| 0510 | <1% | 318 | $4K | |
| 94729 | <1% | 99 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,306 | $3K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 148 | $3K |
| 99217 | <1% | 138 | $3K | |
| 84550 | <1% | 591 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,125 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,173 | $3K |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 147 | $3K |
| 82948 | <1% | 726 | $3K | |
| 94727 | <1% | 99 | $3K | |
| 93880 | <1% | 30 | $3K | |
| 96367 | <1% | 99 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,872 | $3K |
| 96376 | <1% | 41 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 65 | $3K |
| 73590 | <1% | 153 | $3K | |
| 72070 | <1% | 104 | $3K | |
| 0272 | <1% | 10,105 | $3K | |
| 86762 | <1% | 157 | $3K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 384 | $3K |
| 0750 | <1% | 571 | $2K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 187 | $2K |
| 29515 | <1% | 209 | $2K | |
| 86592 | <1% | 989 | $2K | |
| 0301 | <1% | 11,141 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,095 | $2K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 699 | $2K |
| J1815 | Injection, insulin, per 5 units | <1% | 183 | $2K |
| 82570 | <1% | 326 | $2K | |
| 73140 | <1% | 97 | $2K | |
| 84481 | <1% | 90 | $2K | |
| 92950 | <1% | 12 | $2K | |
| 73620 | <1% | 111 | $2K | |
| 88342 | <1% | 43 | $2K | |
| 87186 | <1% | 139 | $2K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 59 | $1K |
| 96368 | <1% | 75 | $1K | |
| 85652 | <1% | 468 | $1K | |
| 76870 | <1% | 24 | $1K | |
| 84144 | <1% | 40 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,134 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,768 | $1K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 34 | $1K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 27 | $1K |
| 29999 | <1% | 14 | $1K | |
| 0370 | <1% | 1,973 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 220 | $1K |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 201 | $1K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 661 | $1K |
| 82043 | <1% | 104 | $940.98 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 124 | $898.47 |
| Z7514 | <1% | 13 | $760.11 | |
| 96379 | <1% | 118 | $715.39 | |
| 80076 | <1% | 66 | $706.06 | |
| 82550 | <1% | 82 | $652.09 | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 13 | $634.44 |
| 0271 | <1% | 10,518 | $565.20 | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 12 | $564.88 |
| 36600 | <1% | 127 | $550.43 | |
| 86803 | <1% | 25 | $527.92 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 15 | $497.54 |
| 82728 | <1% | 189 | $496.02 | |
| 82951 | <1% | 28 | $485.21 | |
| 82607 | <1% | 29 | $417.06 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 220 | $396.80 |
| 87210 | <1% | 56 | $363.27 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 38 | $353.03 |
| 10060 | <1% | 24 | $349.56 | |
| 82010 | <1% | 34 | $336.92 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 82 | $327.69 |
| 73552 | <1% | 13 | $315.39 | |
| 84403 | <1% | 12 | $281.40 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 344 | $274.36 |
| 51702 | <1% | 19 | $269.70 | |
| 81003 | <1% | 104 | $262.48 | |
| 83655 | <1% | 26 | $251.96 | |
| 73060 | <1% | 12 | $228.04 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 509 | $224.14 |
| 0636 | <1% | 10,275 | $214.76 | |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | <1% | 67 | $189.91 |
| 80320 | <1% | 98 | $187.78 | |
| 73600 | <1% | 15 | $186.85 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 42 | $148.79 |
| 0483 | <1% | 2,640 | $146.17 | |
| 0258 | <1% | 3,596 | $131.73 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 56 | $131.16 |
| 84156 | <1% | 42 | $110.27 | |
| 87077 | <1% | 15 | $89.17 | |
| 29105 | <1% | 12 | $72.00 | |
| 0320 | <1% | 1,249 | $68.18 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 133 | $64.56 |
| 87400 | <1% | 13 | $60.19 | |
| 29130 | <1% | 12 | $60.00 | |
| 87205 | <1% | 14 | $57.82 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 34 | $51.50 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 13 | $47.47 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 66 | $37.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 45 | $26.71 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 34 | $21.81 |
| 0306 | <1% | 6,887 | $8.72 | |
| 0307 | <1% | 7,965 | $2.51 | |
| 0921 | 0% | 1,472 | $0.00 | |
| 0730 | 0% | 5,958 | $0.00 | |
| 0300 | 0% | 11,037 | $0.00 | |
| 76818 | 0% | 137 | $0.00 | |
| 0412 | 0% | 2,473 | $0.00 | |
| 0312 | 0% | 1,841 | $0.00 | |
| 0351 | 0% | 2,009 | $0.00 | |
| 0402 | 0% | 2,277 | $0.00 | |
| 0424 | 0% | 954 | $0.00 | |
| 0343 | 0% | 775 | $0.00 | |
| 0381 | 0% | 428 | $0.00 | |
| 0361 | 0% | 975 | $0.00 | |
| 0460 | 0% | 451 | $0.00 | |
| 0302 | 0% | 5,329 | $0.00 | |
| 0920 | 0% | 1,973 | $0.00 | |
| 0722 | 0% | 703 | $0.00 | |
| 0260 | 0% | 2,295 | $0.00 | |
| 0390 | 0% | 60 | $0.00 | |
| 0278 | 0% | 1,455 | $0.00 | |
| 0259 | 0% | 9,241 | $0.00 | |
| 0740 | 0% | 334 | $0.00 | |
| 0771 | 0% | 1,289 | $0.00 | |
| 0310 | 0% | 337 | $0.00 | |
| 0610 | 0% | 25 | $0.00 | |
| 0410 | 0% | 3,453 | $0.00 | |
| 94761 | 0% | 30 | $0.00 | |
| 0482 | 0% | 313 | $0.00 | |
| 0305 | 0% | 10,137 | $0.00 | |
| 0324 | 0% | 6,925 | $0.00 | |
| 0352 | 0% | 4,475 | $0.00 | |
| 0420 | 0% | 929 | $0.00 | |
| 0720 | 0% | 1,159 | $0.00 | |
| 0341 | 0% | 802 | $0.00 | |
| 0801 | 0% | 188 | $0.00 | |
| 0611 | 0% | 198 | $0.00 | |
| 0275 | 0% | 40 | $0.00 | |
| 0761 | 0% | 61 | $0.00 | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | 0% | 34 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOAN, CHRISTOPHER (MANAGING ASSOCIATE GENERAL COUNSEL)
Parent organizationPRIME HEALTHCARE SERVICES
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.